Adding the BCL2 inhibitor venetoclax to endocrine therapy does not improve clinical benefit for ER-positive, HER2-negative, locally advanced/metastatic breast cancer patients.
Risankizumab treatment leads to better-than-placebo signs and symptoms in active PsA patients with inadequate response or intolerance to 1 or 2 biologic therapies or at least one DMARD therapy.
First phase-3 CheckMate 648 study results demonstrate higher first-line treatment OS with nivolumab + ipilimumab, or nivolumab + chemotherapy, versus chemotherapy only.
esanum provides an overview of how you as a medical professional can help and proactively support humanitarian and medical aid projects.
A study investigated the safety profiles of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases (RMD) finding that these vaccines are safe and well tolerated in these patients.
A CheckMate 9LA trial update shows sustained benefit of first-line treatment with nivolumab plus ipilimumab plus 2 cycles of chemotherapy versus chemotherapy alone in patients with advanced NSCLC.
On 31 May 2021 China's National Health Commission notified WHO of one confirmed case in Zhenjiang City, Jiangsu Province. The patient is in a stable condition.
Addition of 177Lu-PSMA-617 therapy to standard of care for mCRPC patients significantly improves survival, according to the phase-3 VISION trial results.
RBN-2397 is a potent, selective inhibitor of PARP7 that could potentially release the brake on the antitumour immunity, is well tolerated, and demonstrated proof of mechanism in a first-in-human trial.
Severe COVID-19 outcomes risk in RA patients is 4 times higher for rituximab, and 2 times higher for JAK inhibitor users compared to TNF inhibitor users. This was not found for abatacept or IL-6-inhibiting DMARDs.
Secukinumab significantly increased the time leading to, and reduced the number of flares in children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) when compared with placebo.
First results of the GAIN/iCAT2 Consortium trial show the importance of molecular profiling for the diagnosis and treatment of solid tumours in young patients.
In patients with severe COVID-19 pneumonia and hyper-inflammation, mavrilimumab was associated with decreased mechanical ventilation and death compared with placebo.
PET/CT showed a discriminating value in measuring disease activity in large-vessel vasculitis (LVV). This finding was consistent in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK) subgroups.
In patients with VERA on methotrexate + tocilizumab combination therapy, ultrasound imaging was able to detect treatment response in an earlier stage than clinical examination scores.
During the COVID-19 pandemic, rheumatoid arthritis remote management is a feasible alternative for routine outpatient follow-up according to a prospective, longitudinal real-world study of UK patients.
Breast cancer has a greater impact on the quality of life and work of those affected than previously assumed,as found by an ongoing study focused on women with breast cancer during therapy.
MDA following a treat-to-target strategy in early PsA can be predicted by a combination of factors, including Tender Joint Count, PGA of disease activity, pain, and the absence of enthesitis and dactylitis.
Exposure to passive smoking in childhood and/or adulthood is associated with RA increased risk, according to the large prospective E3N-EPIC cohort study of French women.
In a recent study, a significant improvement in PFS probability was observed in the treatment of patients with advanced castration-resistant prostate cancer through the use of ribociclib, docetaxel and prednisone.